Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
CAR-T Meeting 2022
#iwHRMM26 | Kicking off session 3 on NSD2/MMSET disease subsets is Benjamin Barwick of @EmoryUniversity by discussing targeting NSD2 and NSD2-dependent biology in t(4;14) #MultipleMyeloma.
#Myeloma #MMsm #HemOnc
Next up: @ZanwarSaurabh of @MayoClinic discussing single-cell transcriptional states in EMD and pPCL.
#iwHRMM26 #MMsm #MultipleMyeloma
#iwHRMM26 | How may biological immune age predict survival and signal #CART response in #multiplemyeloma?
Manoj Bhasin of @EmoryMedicine is on stage right now, discussing this topic.
#Myeloma #MMsm #ImmunoOnc
Kylee Machlachlan of @MSKCancerCenter is next in session 2 with her talk on 'Paramedullary/extramedullary #myeloma dataset'.
#MultipleMyeloma #MMsm #HemOnc #iwHRMM26
#iwHRMM26 | Session 2 has started, and @juanjogrcs is currently on stage discussing non-invasive bone marrow surrogates for high-risk #multiplemyeloma.
#MMsm #Myeloma #BMTsm
CAR-T Meeting 2022
#iwHRMM26 | Kicking off session 3 on NSD2/MMSET disease subsets is Benjamin Barwick of @EmoryUniversity by discussing targeting NSD2 and NSD2-dependent biology in t(4;14) #MultipleMyeloma.
#Myeloma #MMsm #HemOnc
Next up: @ZanwarSaurabh of @MayoClinic discussing single-cell transcriptional states in EMD and pPCL.
#iwHRMM26 #MMsm #MultipleMyeloma
#iwHRMM26 | How may biological immune age predict survival and signal #CART response in #multiplemyeloma?
Manoj Bhasin of @EmoryMedicine is on stage right now, discussing this topic.
#Myeloma #MMsm #ImmunoOnc
Kylee Machlachlan of @MSKCancerCenter is next in session 2 with her talk on 'Paramedullary/extramedullary #myeloma dataset'.
#MultipleMyeloma #MMsm #HemOnc #iwHRMM26
#iwHRMM26 | Session 2 has started, and @juanjogrcs is currently on stage discussing non-invasive bone marrow surrogates for high-risk #multiplemyeloma.
#MMsm #Myeloma #BMTsm
